Regeneron: Dupixent-Led Growth, EYLEA Franchise Stabilization, and High-Value Pipeline Catalysts Underpin Buy Rating

Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron today and set a price target of $1,057.00.

John Newman has given his Buy rating due to a combination of factors tied to both Regeneron’s current product strength and its future pipeline. He expects Dupixent to remain a powerful growth engine through 2026, with multiple approved uses and additional expansion opportunities that should meaningfully support revenue and margin improvement as payments to Sanofi wind down. Although legacy EYLEA 2mg is facing competitive pressure, he anticipates overall franchise stabilization, supported by EYLEA HD growth, recent label expansions, and the expected 2026 launch of a pre-filled syringe that should improve convenience and help sustain the brand. Newman also highlights the potential for upside from strategic discounting aimed at retaining EYLEA share and encouraging transitions to higher-value EYLEA HD.

Beyond the existing portfolio, Newman points to several pipeline and strategic catalysts that could augment Regeneron’s valuation. Upcoming data for oncology candidate fianlimab in combination with cemiplimab, as well as the obesity-focused trevogrumab program, could open new high-value markets. He also notes that rare disease assets such as DB-OTO for genetic hearing loss and garetosmab for FOP may secure regulatory approvals in 2026, potentially acting as additional share price drivers. Moreover, he underscores that his current price target does not yet factor in potential contributions from promising programs like the Factor XI anticoagulation franchise, leaving room for positive surprises, and he sees the possibility of more assertive share repurchases as another lever that could enhance shareholder returns.

In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $860.00 price target.